The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
Zachary Crees, MD, Washington University School of Medicine, St. Louis, MO, discusses a prospective study (NCT06547112) evaluating motixafortide plus granulocyte colony-stimulating factor (G-CSF) for hematopoietic stem cell (HSC) mobilization following quadruplet induction therapy in patients (pts) with multiple myeloma (MM). The study demonstrated that HSC mobilization success remained relatively high when compared to data from the pivotal GENESIS trial (NCT03246529), despite the reduced mobilization efficiency and effectiveness associated with CD38 monoclonal antibody–based quadruplet induction. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
